[go: up one dir, main page]

MX2019005779A - Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina. - Google Patents

Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.

Info

Publication number
MX2019005779A
MX2019005779A MX2019005779A MX2019005779A MX2019005779A MX 2019005779 A MX2019005779 A MX 2019005779A MX 2019005779 A MX2019005779 A MX 2019005779A MX 2019005779 A MX2019005779 A MX 2019005779A MX 2019005779 A MX2019005779 A MX 2019005779A
Authority
MX
Mexico
Prior art keywords
disorders
methods
flupirtine
seizure
treating developmental
Prior art date
Application number
MX2019005779A
Other languages
English (en)
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2019005779A publication Critical patent/MX2019005779A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan métodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina o una sal farmacéuticamente aceptable de la misma. Los métodos proporcionan composiciones terapéuticas que se pueden usar para mejorar uno o más síntomas del trastorno del desarrollo y/o trastorno convulsivo.
MX2019005779A 2016-11-22 2017-11-21 Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina. MX2019005779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662425309P 2016-11-22 2016-11-22
PCT/US2017/062685 WO2018098111A1 (en) 2016-11-22 2017-11-21 Methods of treating developmental disorders and/or seizure disorders with flupirtine

Publications (1)

Publication Number Publication Date
MX2019005779A true MX2019005779A (es) 2019-08-22

Family

ID=62144547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005779A MX2019005779A (es) 2016-11-22 2017-11-21 Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.

Country Status (10)

Country Link
US (3) US20180140586A1 (es)
EP (1) EP3528807A4 (es)
JP (1) JP2019535760A (es)
KR (1) KR20190086709A (es)
CN (1) CN110225754A (es)
AU (2) AU2017363598A1 (es)
CA (1) CA3043626A1 (es)
IL (1) IL266764A (es)
MX (1) MX2019005779A (es)
WO (1) WO2018098111A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016295138B2 (en) 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
WO2020047603A1 (en) * 2018-09-06 2020-03-12 Monash University Method of treating a sleep breathing disorder
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
JP2022514275A (ja) 2018-12-17 2022-02-10 オービッド・セラピューティクス・インコーポレイテッド 非２４時間型睡眠覚醒障害の処置のためのガボキサドールの使用
JP2022540917A (ja) * 2019-07-15 2022-09-20 オービッド・セラピューティクス・インコーポレイテッド 治療的処置のためのガボキサドール含有医薬製剤
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
KR102415692B1 (ko) * 2020-09-01 2022-07-05 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물
WO2023281103A1 (en) * 2021-07-08 2023-01-12 Nls Pharmaceutics Ag Benedin, piperidine, 2-benzhydryl-3-hydroxy-n-methyl-, hydrochloride and derivatives thereof for use in treating kleine-levin syndrome

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4581277B2 (ja) * 2000-03-28 2010-11-17 味の素株式会社 非意図的行動抑制用医薬組成物、および、ランニングニューロン抑制物質の該医薬組成物製造のための使用
AUPR220300A0 (en) * 2000-12-20 2001-01-25 Bionomics Limited New epilepsy gene
MXPA05013016A (es) * 2003-06-25 2006-03-02 Lundbeck & Co As H Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
WO2005023256A1 (en) * 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
CA2550023C (en) * 2003-12-16 2011-04-12 Cnsbio Pty Ltd Treatment of neuropathic pain
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
MXPA06011325A (es) * 2004-04-02 2006-12-15 Lundbeck & Co As H Tratamiento de la funcion respiratoria alterada con gaboxadol.
WO2006118897A1 (en) * 2005-04-29 2006-11-09 H.Lundbeck A/S Acid and base salt forms of gaboxadol
EP2012769A1 (en) * 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8597880B2 (en) * 2007-10-02 2013-12-03 The Fred Hutchinson Cancer Research Center Methods and compositions for identifying increased risk of developing fragile X-associated disorders
US9212155B2 (en) * 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
CA2891855A1 (en) * 2012-12-21 2014-06-26 Sykehuset Sorlandet Hf Egfr targeted therapy of neurological disorders and pain
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2015069988A1 (en) * 2013-11-07 2015-05-14 Kindred Biosciences, Inc. Treatment of pain in animals
PT3151832T (pt) * 2014-06-06 2021-06-15 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a insónia secundária
US20170296561A1 (en) * 2014-09-25 2017-10-19 Cold Spring Harbor Laboratory Treatment of rett syndrome
CN115487313A (zh) * 2015-02-06 2022-12-20 马瑞纳斯制药公司 静脉内加奈索酮制剂及其用途
AU2016295138B2 (en) * 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol

Also Published As

Publication number Publication date
AU2017363598A1 (en) 2019-05-23
WO2018098111A1 (en) 2018-05-31
EP3528807A4 (en) 2020-06-17
AU2021257943A1 (en) 2021-11-25
US20190105308A1 (en) 2019-04-11
JP2019535760A (ja) 2019-12-12
CN110225754A (zh) 2019-09-10
EP3528807A1 (en) 2019-08-28
CA3043626A1 (en) 2018-05-31
US20190328719A1 (en) 2019-10-31
IL266764A (en) 2019-07-31
KR20190086709A (ko) 2019-07-23
US20180140586A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
MX2023009483A (es) Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia.
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
MX2023009631A (es) Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi.
EA201691582A1 (ru) Новые фармацевтические препараты
MX381640B (es) Metodos y compuestos agonistas de gip.
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2015017253A (es) Composiciones y metodos para tratar trastornos metabolicos.
AU2022221400B2 (en) Methods of treating metabolic disorders with FGF21 variants
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
IL275349A (en) Use of hM4Di in the treatment of seizure disorders
MX2019000677A (es) Células miméticas de células b.
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
MX2020007162A (es) Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina.
IL274838A (en) Use of MIR101 or MIR128 in the treatment of seizure disorders
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
HK40037135A (en) Use of hm4di in the treatment of seizure disorders